APA (7th ed.) Citation

Judge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R., . . . Herrington, W. G. (2025). The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): A rationale for the EASi-KIDNEY trial. Nephrology, dialysis, transplantation, 40(6), . https://doi.org/10.1093/ndt/gfae263

Chicago Style (17th ed.) Citation

Judge, Parminder K., et al. "The Potential for Improving Cardio-renal Outcomes in Chronic Kidney Disease with the Aldosterone Synthase Inhibitor Vicadrostat (BI 690517): A Rationale for the EASi-KIDNEY Trial." Nephrology, Dialysis, Transplantation 40, no. 6 (2025). https://doi.org/10.1093/ndt/gfae263.

MLA (9th ed.) Citation

Judge, Parminder K., et al. "The Potential for Improving Cardio-renal Outcomes in Chronic Kidney Disease with the Aldosterone Synthase Inhibitor Vicadrostat (BI 690517): A Rationale for the EASi-KIDNEY Trial." Nephrology, Dialysis, Transplantation, vol. 40, no. 6, 2025, https://doi.org/10.1093/ndt/gfae263.